Don't miss the opportunity to be one of the first to experience the Revio system in Asia-Pacific. Elevate your research to new heights by participating in the 2023 APAC Revio HiFi Sequencing Experience Grant.
At 15x increase in HiFi read throughput on the Revio system, you can receive up to 360 Gb of HiFi reads per day, that's 1,300 human whole genomes per year!
Expect faster results with 24-hour run time, and flexibility to queue runs while sequencing is in progress.
With 20x more compute power and Google DeepConsensus on board, you get exceptional read accuracy plus methylation calling in every run.
Sequencing cost is now signifcantly lower on Revio, making long-read sequencing at scale more affordable.
At PacBio, we are passionate about accuracy in sequencing data. If your research could benefit from highly accurate long-read sequencing, apply to this 2023 APAC Revio HiFi Sequencing Experience Grant today!
Because you need sequencing data you can trust for advanced biological insights.
HiFi reads are both long (up to 25 kb) and highly accurate (99.9%) to achieve complete, contiguous, and correct assemblies of even the most complex genomes with minimal compute resources.
HiFi reads offer best-in-class detection of all variant types including single nucleotide variants (SNVs), indels, structural variants (SVs), repeat expansions, epigenetic variations, etc.
Submit your proposal by
30 September 2023
Ready to learn more about HiFi sequencing to prepare for your proposal?
Get to know the A-T-C-Gs of this PacBio HiFi Sequencing Experience Grant
|Act fast – This HiFi-SeqXP Grant is only open for a short time, so there is no time to wait. The deadline for submitting your proposal titles is 30 September 2023 at 23:59 (Singapore time).|
|Tell us about your research – Projects large and small will be considered, with the possibility of multiple winners across human genomics, microbial genomics, oncology and plant and animal genomics. Up to 24 Revio SMRT Cells worth of sequencing and associated library preps is up for grabs.|
|Connect and inspire – We encourage scientists of all career stages to apply, so share this opportunity with your colleagues and win sequencing on the first few Revio units in APAC with the option of HiFi data analysis.|
|Get in touch – We are here to answer your questions about this HiFi Sequencing Experience or the official rules.|
The Bio-X Institutes of Shanghai Jiao Tong University was formed in 2005 by merging the Neuropsychiatric and Human Genetics Group (NHGG), which was established in 1996, and the Bio-X Life Science Research Institutes, which was established in April 2000. The founding of the Bio-X Institutes represents a landmark in interdisciplinary research among the life sciences. The mission of the Institutes is to provide not only an interdisciplinary institute, but also to serve as a forum for discussion among scientists and students from a variety of disciplines and fields. To learn more about Bio-X Institutes, visit them at www.bio-x.cn.
Kindstar Sequenon Co., Ltd. is a subsidiary of Kindstar Global, which provides medical multi-omics research services and clinical LDT transformation. The core team of Kindstar Sequenon all graduated from well-known universities in the field of life medicine in China and abroad, and the proportion of employees with master's and doctoral degrees is over 60%. All employees have more than 5 years of experience in multi-group scientific research services, and have their own advantages and characteristics in the fields of third-generation sequencing, NGS, single-cell sequencing, etc. At the same time, the company has equipped an experienced bioinformatics advanced analysis and article improvement service team. Kindstar Sequenon is equipped with sequencing platforms such as PacBio Revio, NovaSeq 6000, NovaSeq X Plus, ABI 3700xl; 10x Genomics single-cell system, Sorting Flow Cytometry, digital PCR, and other instruments. Kindstar Sequenon will provide comprehensive and rich medical research services to researchers, hospitals, scientific research institutions and biopharmaceutical companies in the field of biomedicine in China and abroad, and will promote the development and transformation of multi-disease LDT based on multi-omics technology.To learn more about Kindstar Sequenon, visit them at kindstar.com.cn
Kazusa DNA Research Institute was founded in 1994 and inaugurated its activity as the world's first institute specialized in DNA-related research. All members of the institute are highly motivated to continuously explore and widen DNA-related research fields, thereby contributing to our society in broad aspects of medicine, agriculture, industry and education. To learn more about Kazusa DNA Research Institute, visit them at www.kazusa.or.jp.
Next Level Genomics is a dedicated PacBio long-read sequencing centre with experienced and trained scientists in genomics and bioinformatics. Our lab is available to everyone looking to bring the power of long-read technology to their work – and do it with a team of experts behind you. To learn more about Next level Genomics, visit them at www.nextlevelgenomics.com.
Macrogen was established on June 5, 1997, based in the Genomic Medicine Institute of the Seoul National University College of Medicine. In February 2000. It is the first Korean bio venture to be listed on the KOSDAQ. Since then, Macrogen has continued to be actively engaged in R&D fields for genetic and genomic analyses. In addition to providing services to clients around the world, Macrogen contributes to the advancement of bioindustries through a wide range of CSR activities. Macrogen is committed to leading innovation in precision medicine in the 21st century by providing personalized genomic information. It is also realizing achievements in the global genome analysis market in various sectors, thanks to its superior technological expertise. To learn more about Macrogen, visit them at www.macrogen.com.
With the goal of becoming a “Frontier Company in Personalized Medicine”, DNA Link, Inc. produces high-quality data by analysis of genomic information on all species through up-to-date technologies, constructs DB on genomic information to investigate genomic traits in groups through data analysis and interpretation, discovers genomic biomarkers through converged genomic analysis, and strives to lead personalized medicine and new drug development by converging bio technology and information & communications technology to support total analysis of genomic and clinical information. DNA Link, Inc.’s ultimate goal is to improve the health and quality of life of all mankind globally. To learn more about DNALink, visit them at dnalink.com
Welgene Biotech was founded in 2003 and located in Taipei City, Taiwan. Welgene provides Iso-seq, 16S rDNA full length sequencing, bacteria genome sequencing, metagenomics sequencing, whole human genome sequence, de novo genome sequencing, next generation sequencing, microarray, and bioinformatics services to academy or clinics. To learn more about Welgene, visit them at www.welgene.com.tw.